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At a time when the twin epidemics of obesity and type 2 diabetes threaten to engulf even the most well-resourced Western health-
care systems, the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) has emerged as a bona fide therapeutic
target for treating human metabolic disease. The novel insulin-sensitizing antidiabetic thiazolidinediones (TZDs, e.g., rosiglita-
zone, pioglitazone), which are licensed for use in the treatment of type 2 diabetes, are high-aﬃnity PPARγ ligands, whose beneficial
eﬀects extend beyond improvement in glycaemic control to include amelioration of dyslipidaemia, lowering of blood pressure, and
favourable modulation of macrophage lipid handling and inflammatory responses. However, a major drawback to the clinical use
of exisiting TZDs is weight gain, reflecting both enhanced adipogenesis and fluid retention, neither of which is desirable in a popu-
lation that is already overweight and prone to cardiovascular disease. Accordingly, the “search is on” to identify the next generation
of PPARγ modulators that will promote maximal clinical benefit by targeting specific facets of the metabolic syndrome (glucose
intolerance/diabetes, dyslipidaemia, and hypertension), while simultaneously avoiding undesirable side eﬀects of PPARγ activa-
tion (e.g., weight gain). This paper outlines the important clinical and laboratory observations made in human subjects harboring
genetic variations in PPARγ that support such a therapeutic strategy.
Copyright © 2007 Mark Gurnell. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The health of a nation has long been recognized to be a func-
tion of its wealth. Traditionally, countries with limited re-
sources have struggled to eradicate diseases that are often
considered a thing of the past in so-called “developed” or
“industrialized” nations. However, in recent years it has be-
come clear that wealth does not always equate with good
health. Indeed, we now face the very real possibility that in
the first half of this century, average life expectancy in in-
dustrialized countries such as the US and UK will plateau
or decline, despite continuing economic growth and pros-
perity [1]. The obesity epidemic, which is currently sweep-
ing through “Western civilization,” is undoubtedly the sin-
gle biggest factor behind this “unwanted reversal” [1]. Re-
cent figures from the US reveal an alarming 75% increase in
the prevalence of obesity over the past 25 years, such that a
third of the population is now oﬃcially obese, that is to say, at
least 20% heavier than their ideal weight [2]. Many Western
European countries and Japan are not far behind. Obesity
is a major risk factor for insulin resistance, type 2 diabetes
mellitus (T2DM), hypertension, and dyslipidaemia (partic-
ularly hypertriglyceridaemia and low high-density lipopro-
tein cholesterol (HDL-C)); this cluster of medical sequelae is
often grouped together under the umbrella term “metabolic
syndrome,” and over the past decade the thresholds that must
be met for the diagnosis of this entity have been progressively
refined, culminating most recently in a consensus statement
from the International Diabetes Federation (Table 1). Not
surprisingly, subjects whomeet the diagnostic criteria for this
disorder are at significantly increased risk of atherosclerotic
cardiovascular disease (reviewed in [3]).
So how can we arrest/reverse this apparently relentless
march towards “metabolic meltdown”? The solution seems
obvious: more eﬀective obesity prevention and treatment.
Limiting caloric intake and increasing energy expenditure
to promote neutral (or in obese subjects negative) rather
than positive energy balance is likely to yield enormous ben-
efits at both the individual and population levels. Indeed,
“lifestyle intervention” studies have already convincingly
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Table 1: Diagnostic criteria for the human metabolic syndrome. WHO, World Health Organization; EGIR, European Group for the Study
of Insulin Resistance; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; IDF, International Diabetes Feder-
ation; T2DM, type 2 diabetes mellitus; IGT, impaired glucose tolerance; IR, insulin resistance; TG, triglycerides; HDL, high density lipopro-
tein cholesterol; BP, blood pressure; BMI, body mass index; WHR, waist hip ratio; WC, waist circumference; AER, albumin excretion rate;
M, male; F, female.
WHO, 1999 EGIR, 1999 NCEP ATP III, 2001 IDF, 2005
T2DM or IGT or IR
IR or hyperinsulinaemia, in
nondiabetic subjects
Central obesity:
WC ≥ ethnicity specific cut-oﬀs
with ≥2 of the following with ≥2 of the following ≥3 of the following with ≥2 of the following
Hyperglycaemia Hyperglycaemia Hyperglycaemia
Fasting plasma glucose ≥ Fasting plasma glucose ≥ Fasting plasma glucose ≥
6.1mmol/L, but nondiabetic 6.1mmol/L or 5.6mmol/L or
treated with antidiabetic medication. previously diagnosed T2DM
Dyslipidaemia Dyslipidaemia Hypertriglyceridaemia Hypertriglyceridaemia
TG >1.7mmol/L and/or TG >2.0mmol/L or TG ≥1.7mmol/L TG >1.7mmol/L or
HDL <0.9mmol/L (M) HDL <1.0mmol/L or treated for this lipid abnormality
HDL <1.0mmol/L (F) treated for dyslipidaemia
Low HDL cholesterol Reduced HDL cholesterol
HDL <1.0mmol/L (M) HDL <1.03mmol/L (M)
HDL <1.3mmol/L (F) HDL <1.29mmol/L (F) or
treated for this lipid abnormality
Hypertension Hypertension Hypertension Hypertension
BP ≥140/90mmHg±medication BP ≥140/90mmHg or BP ≥130/85mmHg or BP ≥130/85mmHg or
treated for hypertension treated for hypertension treated for hypertension
Obesity Central obesity Central obesity Central obesity
BMI ≥30 kg/m2 or WC ≥94 cm (M) WC ≥102 cm (M) See above—core requirement for
WHR >0.9 (M) WC ≥80 cm (F) WC ≥88 cm (F) diagnosis of syndrome
WHR >0.85 (F)
Microalbuminuria
Urinary AER >20mcg/min
demonstrated that the risk of developing complications such
as T2DM can be significantly reduced using such an ap-
proach [4, 5]. Unfortunately however, while this is a laud-
able goal, most clinicians know only too well that in prac-
tice it is very diﬃcult to achieve/sustain, and hence attention
has turned towards seeking novel therapies that are capable
of ameliorating/reversing weight gain, insulin resistance, and
their unwanted sequelae. Understanding the genes that are
involved in maintaining metabolic homeostasis in the face of
diﬀering nutritional and environmental stresses is essential
to the rational development of these strategies.
In recent years, a group of transcription factors belonging
to the nuclear receptor superfamily has emerged as key play-
ers in the regulation of mammalian metabolism. Peroxisome
proliferator-activated receptor γ(PPARγ) is perhaps the best
characterized of these so-called metabolic nuclear receptors,
serving as it does to integrate the control of energy, glucose,
and lipid homeostasis. The activity of PPARγ is governed by
the binding of small lipophilic ligands, principally fatty acids,
derived from nutrition or metabolism [6, 7], and activation
of the receptor is a critical step in the pathway to adipocyte
diﬀerentiation and fat cell maturation. Hence, it is easy to en-
visage how chronic exposure to high levels of dietary PPARγ
ligands (provided in abundance in the Western diet) could
promote the development of obesity, insulin resistance, and
metabolic dysfunction, and why receptor modulation might
oﬀer a route to prevention/amelioration of these important
cardiovascular risk factors. Indeed, drugs targeting PPARγ
activity (thiazolidinediones (TZDs), e.g., rosiglitazone, pi-
oglitazone) are already in widespread clinical use as eﬀec-
tive antidiabetic agents, enhancing insulin sensitivity, elevat-
ing high-density lipoprotein cholesterol (HDL-C) levels, and
lowering blood pressure [8]. Importantly other studies have
begun to examine whether these agents actually lower cardio-
vascular event rates [9], and if they are capable of reducing
the risk of progression to overt T2DM in those with existing
impaired glucose regulation [10].
Paradoxically however, TZDs actually promote weight
gain rather than weight loss. A significant part of this increase
can be attributed to enhanced adipogenesis, consistent with
TZDs acting as high-aﬃnity agonists for PPARγ [11–13]. In
addition, fluid retention and expansion of the extracellular
compartment (possibly through altered renal sodium han-
dling [14]) may contribute to weight gain in some patients,
especially those with preexisting cardiac impairment [15].
Together, these observations raise an important question: is
it possible to developmore selective PPARγmodulators, with
even greater potential to improve metabolic dysfunction, yet
at the same time with reduced propensity to cause weight
gain and fluid retention? Clearly, the answer to this question
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is dependent on the basic biology of PPARγ and whether it
proves possible to regulate receptor function in a tissue- and
a target-gene-specific manner.
This paper summarizes the important contributions that
human genetic studies have made to our understanding of
the role of PPARγ in the regulation of mammalian metabolic
homeostasis, emphasizing the potential benefits and limita-
tions that we can expect from more targeted approaches to
modulating receptor function, and thus ensuring that in an
era marked by an increasing prevalence of obesity, diabetes
and cardiovascular disease, PPARγ remains more of “a help”
than “a hindrance.”
2. PPARγ-STRUCTURE, FUNCTION, AND
LIGAND REGULATION
The human nuclear receptor superfamily comprises 48
ligand-inducible transcription factors that respond to a va-
riety of stimuli including steroid and thyroid hormones,
vitamins, lipid metabolites, and xenobiotics. PPARγ is the
third member of a subdivision within the superfamily that
also includes PPARα and PPARδ [25, 26]. Together, the
PPARs function as key transcriptional regulators that govern
metabolic homeostasis by serving as lipid sensors, respond-
ing to dietary fatty acids and their derivatives. However, each
has a distinct pattern of tissue expression, and consistent with
this, specific roles in the regulation of energymetabolism (re-
viewed in [25, 26]). The importance of these receptors in
physiology and disease is evidenced by the fact that PPARα
and PPARγ are themolecular targets for the lipid-lowering fi-
brate class of drugs and TZDs, respectively, while PPARδ lig-
ands are currently being developed in anticipation that they
will oﬀer a novel approach to tackling obesity and metabolic
dysfunction through eﬀects on energy expenditure, HDL-C
metabolism, and macrophage inflammatory responses (re-
viewed in [26]).
Diﬀerential promoter usage, coupled with alternate splic-
ing of the PPARG gene, generates two protein isoforms:
PPARγ2, expressed from a single γ2 promoter, contains an
additional 28 N-terminal amino acids and is nearly adipose-
specific; PPARγ1, whose expression can be regulated by mul-
tiple (γ1, γ3, γ4) promoters, is more ubiquitously distributed
[27–29]. Like other nuclear receptors, PPARγ exhibits a
modular structure consisting of distinct functional domains:
the N-terminal A/B domain harbors a ligand-independent
transcriptional activation function (AF1), which is stronger
for the γ2 than γ1 isoform; the central DNA-binding domain,
containing two zinc finger motifs, facilitates interaction with
specific binding sites (PPAR response elements (PPREs)) in
target gene promoters; the larger C-terminal domain medi-
ates ligand-binding, heterodimerization with the retinoid X
receptor (RXR), and contains a powerful ligand-dependent
activation (AF2) function (Figure 1(a)).
Initially, PPARγ was considered to be a constitutively
active receptor, recruiting transcriptional coactivators (e.g.,
steroid receptor coactivator-1 (SRC-1)) to classical target
genes (e.g., adipocyte protein 2 (aP2)) even in the absence of
ligand. More recently however, Guan et al. have shown that
the unliganded PPARγ/RXR heterodimer can actively silence
a subset of genes (e.g., adipocyte glycerol kinase (GyK)), in
a manner analogous to that seen with the thyroid hormone
(TR) and retinoic acid (RAR) receptors [24] (Figure 1(b)).
Transcriptional silencing is mediated through recruitment
of a multiprotein corepressor complex, containing either
NCoR (nuclear receptor corepressor) or SMRT (silencing
mediator of retinoic acid and thyroid receptors), together
with histone-modifying enzymes (e.g., histone deacetylase 3
(HDAC 3)), which condense chromatin structure, thus im-
peding gene transcription. In contrast, binding of cognate
or exogenous ligand(s) induces a conformational change
in the heterodimer such that it now dissociates from any
bound corepressor proteins and instead recruits a coacti-
vator complex, containing histone acetyltransferases (e.g.,
CREB-binding protein (CBP)), which relaxes the chromatin
structure so as to permit greater levels of gene transcription
(Figure 1(c)).
A variety of putative endogenous activators has been de-
scribed for PPARγ, including fatty acids, eicosanoids, and
derivatives of oxidized low-density lipoproteins [30]. The
prostaglandin J2 derivative 15-deoxy-Δ12,14-PGJ2 is also ca-
pable of activating PPARγ in vitro, although it is doubtful
as to whether it exists at suﬃcient concentrations in vivo to
serve as a physiological ligand. Recently, Tzameli et al. have
reported the existence of an as yet undefined ligand(s) that is
produced transiently during adipocyte diﬀerentiation [31].
3. PPARγ-A KEY THERAPEUTIC TARGET IN
THE HUMANMETABOLIC SYNDROME
Patients with the metabolic syndrome typically require a
“cocktail of drugs” to treat the individual components of
the disorder and its associated atherosclerotic complications
(e.g., oral hypoglycaemic agents, insulin, statins, fibrates, an-
tihypertensives, aspirin, etc.). Unfortunately, many of these
drugs confer little benefit in terms of correcting the underly-
ing metabolic disturbance, and indeed some even exacerbate
the situation, for example, insulin-induced weight gain. Not
surprisingly then, compliance with these complex treatment
regimens is often poor.
In contrast, drugs that target PPARγ appear, at least in
theory, to oﬀer an attractive and perhaps more logical ap-
proach to treating the metabolic syndrome, by virtue of
their ability to ameliorate insulin resistance and other facets
of the condition [8]. Set against this however is the well-
documented increase in body weight that is observed with
currently available TZDs [8]. It is these observations that
have led scientists and clinicians alike to ask whether it is
possible to retain/enhance the metabolic benefits of PPARγ
activation, yet at the same time minimize undesirable side
eﬀects. The following sections outline the human genetic ev-
idence that supports such a strategy, with specific reference
to each of the key components of the metabolic syndrome.
3.1. PPARγ and adipogenesis
In vitro studies suggest that PPARγ is the ultimate eﬀector of
adipogenesis in a transcriptional cascade that also involves
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Figure 1: Structure function of PPARγ. (a) Schematic representation of the three principal domains of PPARγ, denoting the posi-
tions of several of the natural genetic variants that have been identified in the human receptor. Note that mutations and polymor-
phisms have been depicted based on the nomenclature (γ1 or γ2) used in the primary publication [16–23]. FSX denotes the mutation
(A553ΔAAAiT)fs185(stop186); FS315X denotes the mutation (A935ΔC)fs312(stop315). (b) In the absence of exogenous ligand, PPARγ re-
cruits a corepressor complex to a subset of target genes (e.g., adipocyte glycerol kinase), thereby repressing basal transcription [24]. (c)
Addition of ligand induces a conformational change in the receptor, which promotes corepressor release and coactivator recruitment. For
other target genes (e.g., aP2), the receptor appears to be constitutively active even in the absence of exogenous ligand [24]. NLS denotes nu-
clear localization signal; RXR denotes retinoid X receptor; ID denotes interaction domain; AF2 denotes activation function 2; PPRE denotes
PPAR response element.
members of the C/EBP transcription factor family [32].
Modulation of PPARγ expression and/or action in rodent
cell lines has conclusively shown that the receptor is both es-
sential and, in the presence of PPARγ agonists, is suﬃcient
for adipogenesis [33]. Consonant with this, PPARγ knockout
mice fail to develop adipose tissue [34–36], while their het-
erozygous counterparts have reduced fat depots [36]. Studies
in human tissues point to a similar critical role for PPARγ
in the regulation of adipogenesis. Exposure of cultured pri-
mary human preadipocytes to PPARγ activators (e.g., TZDs)
induces their diﬀerentiation [32], while both chemical and
biological receptor antagonists eﬃciently block this process
[37].
It comes as no surprise then to learn that human sub-
jects treated with synthetic PPARγ agonists (e.g., rosigli-
tazone, pioglitazone) gain weight through enhanced adi-
pogenesis [8]. Despite this, metabolic function in the ma-
jority of TZD recipients improves. This apparent TZD
paradox undoubtedly reflects the ability of these agents
to modify adipocyte function and free fatty acid stor-
age in a favorable manner that promotes insulin sensitiza-
tion; however, it may also be dependent, at least in part,
on PPARγ activation mediating depot-specific rather than
global changes in adipogenesis. For example, it is notable
that the increase in fat mass observed in type 2 diabetics
treated with TZDs is not uniformly distributed, with a ten-
dency to accumulate subcutaneous (e.g., limb/gluteal) fat,
whereas visceral adipose tissue volume is reduced or un-
changed (reviewed in detail in [38]). Consistent with this,
preadipocytes isolated from subcutaneous abdominal adi-
pose tissue have been shown in some (although not all)
studies to diﬀerentiate more readily in response to TZDs
than cells from visceral depots taken from the same subjects
[39].
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Figure 2: Clinical features exhibited by adult subjects harboring loss-of-function mutations in human PPARγ. For each parameter shown,
the numerator denotes the reported number of aﬀected individuals, and the denominator denotes the number of subjects for whom relevant
information is available.
3.1.1. Gain- and loss-of-function mutations
With PPARγ agonists promoting adipogenesis, it would seem
reasonable to speculate that gain-of-function PPARγ mu-
tations should increase body fat mass. Ristow et al. have
provided support for this hypothesis, with the identifica-
tion of four morbidly obese (BMI 37.9 to 47.2 kg/m2) Ger-
man subjects, all of whom harbored a gain-of-function mu-
tation (Pro115Gln PPARγ2) within the N-terminal domain
of the receptor [40]. The transcriptional activity of PPARγ is
subject to modification through phosphorylation of a serine
residue at codon 114 [41, 42], and mutation of the adjacent
proline was shown to interfere with this process, resulting in
a receptor with constitutive transcriptional activity and en-
hanced adipogenic potential [40]. Subsequently however, a
fifth subject, with only a mildly elevated BMI (28.5 kg/m2),
was found to carry the same amino acid substitution, which
is in marked contrast to the findings of the original study
[43]. Thus, for now the significance of this particular genetic
variant remains unclear, and further mutation carriers must
be identified to confirmwhether Pro115Gln does indeed pre-
dispose to obesity and, if so, whether there is a depot-specific
pattern to the accretion of adipose tissue.
In contrast, there is now a compelling body of data from
the study of human subjects with loss-of-function mutations
in PPARγ to confirm a pivotal role for this receptor in human
adipogenesis. To date, twelve diﬀerent heterozygous muta-
tions (missense, nonsense, and frameshift) have been identi-
fied within the DNA- (DBD) and ligand-binding (LBD) do-
mains of the receptor (Figure 1(a)) [16–23], with functional
studies, where available, confirming that the mutant recep-
tors are transcriptionally impaired. In keeping with their
dominant mode of inheritance, several of the mutants have
also been shown to be capable of inhibiting the activity of
their wild-type counterpart in a dominant negative manner,
reflecting either aberrant corepressor recruitment to DNA-
bound mutant receptors [16, 44], or transcriptional inter-
ference through coactivator sequestration by DNA-binding
deficient mutants [23]. In contrast, other mutants appear to
lack dominant negative activity, with the clinical phenotype
purported to be a consequence of haploinsuﬃciency [18, 20–
22]. In keeping with the latter, Al-Shali et al. have recently
identified a kindred harboring a novel heterozygous A > G
mutation at position −14 within intron B of PPARG (up-
stream of exon 1), which reduces promoter activity of the
PPARγ4 isoform [45]. This mutation cosegregated with a
phenotype of partial lipodystrophy and metabolic dysfunc-
tion similar to that observed in subjects harboring loss-of-
function mutations within the DBD or LBD [45].
Together, these reports describe more than twenty adult
subjects, the majority of whom exhibit a stereotyped pat-
tern of partial lipodystrophy, in which subcutaneous fat is
diminished in the limbs and gluteal region, while being pre-
served/increased in the subcutaneous and visceral abdomi-
nal depots (Figure 2) [16–23]. Some phenotypic diﬀerences
have been observed with facial and neck adipose tissues,
which were reported to be increased in individuals from
two kindreds, but normal or reduced in most other cases
[16–23]. These findings are again strongly suggestive of a
depot-specific role for PPARγ in human adipogenesis, and
complement the observations made in diabetic subjects re-
ceiving TZD treatment. Clearly one challenge is to under-
stand why visceral adipose tissue appears relatively refrac-
tory to PPARγ regulation despite expressing comparable lev-
els of receptor to its subcutaneous counterpart. Studies of fat
biopsies from diﬀerent depots in PPARγ mutation carriers
might oﬀer a unique route to addressing this important ques-
tion.
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Interestingly, a transgenic knockin mouse model based
on the human Pro467Leumutation (Pro465Leu) has recently
been reported by two independent groups [46, 47]. Het-
erozygous PpargP465L/+ mice have normal total adipose tis-
sue weight, but exhibit reduced intra-abdominal fat mass
and increased extra-abdominal subcutaneous fat compared
to wild-type (WT) animals, that is, altered body fat distri-
bution, but in a manner which is quite distinct from that
observed in human subjects. In addition, unlike their hu-
man counterparts, the PpargP465L/+ mice were also insulin-
sensitive. These findings initially raised concerns as to the
suitability of using rodent models to explore the conse-
quences of loss-of-functionmutations in human PPARγ. Im-
portantly however, in the model of Gray et al., expression
of the P465L mutant on a hyperphagic ob/ob background
grossly exacerbated the insulin resistance and metabolic dis-
turbances associated with leptin deficiency, despite reducing
whole body adiposity and adipocyte size [47]. Thus, in the
mouse coexistence of the P465L PPARγ mutation and the
leptin-deficient state creates a mismatch between adipose tis-
sue expandability and energy availability, thereby unmask-
ing the deleterious eﬀects of PPARγ mutations on carbohy-
drate metabolism and recapitulating the clinical phenotype
observed in human subjects.
3.1.2. Polymorphisms
The most prevalent human PPARγ genetic variant reported
to date is the Pro12Ala polymorphism, substituting ala-
nine for proline at codon 12 in the unique PPARγ2 amino-
terminal domain [48]. The allelic frequency of the Ala variant
diﬀers quite markedly depending on the study population,
ranging from 1% to 23% [49]. In functional assays, Ala12-
PPARγ exhibits reduced binding to DNA andmodest impair-
ment in target gene transactivation in both the absence and
presence of PPARγ agonists [48]. An association with lower
BMI in the primary study appeared to suggest a correspond-
ing genotype-phenotype correlation, and led to the hypoth-
esis that improved insulin sensitivity might be accounted for
entirely by changes in adiposity [48]. However, numerous
subsequent cross-sectional studies have yielded conflicting
results, demonstrating either no diﬀerence [50] or a mod-
estly greater BMI [51] in carriers of the Ala allele. In an at-
tempt to resolve this issue, Masud and Ye completed a meta-
analysis using data from 30 independent studies with a to-
tal of 19 136 subjects [52]. They concluded that in the sam-
ples with a mean BMI value ≥27 kg/m2, Ala12 allele carri-
ers had a significantly higher BMI than noncarriers, whereas
no diﬀerence was detected in the samples with a BMI value
<27 kg/m2. A further analysis using data from publications
in which BMI for the three genotype groups (i.e., Pro/Pro,
Pro/Ala and Ala/Ala) were presented separately revealed that
the Ala12 homozygotes had significantly higher BMI than
heterozygotes and Pro12 homozygotes [52].
Importantly, the eﬀects of the Ala allele have recently
been shown to be subject to modification by other genetic
and environmental factors, and indeed this may in part ex-
plain the apparently discordant results of the studies reported
hitherto. For example, variations in dietary polyunsaturated
fat versus saturated fat intake appear to influence BMI in car-
riers of the Ala variant [53]. In the Quebec Family Study, car-
riers of the Pro12 allele had lower BMI, waist circumference
and fat mass (both subcutaneous and visceral) at baseline,
but responded to an increase in dietary fat with a gradual in-
crease in BMI and waist circumference, an eﬀect which was
not observed in their Ala counterparts [54]. Together, these
and other studies support the notion of gene-nutrient inter-
action at the PPARγ locus.
3.2. PPARγ and insulin sensitivity
3.2.1. Genetic evidence for a link
Several lines of evidence point to a link between the level of
PPARγ transcriptional activity and insulin sensitivity: (1) the
in vitro binding aﬃnities of TZD and non-TZD PPARγ lig-
ands correlate closely with their in vivo potencies as insulin
sensitizers [11, 55]; (2) RXR ligands, which can activate the
PPARγ-RXR heterodimer, also exhibit insulin-sensitizing ef-
fects in rodents [56]; (3) mice exhibiting enhanced PPARγ
activity, due to a mutation at serine 112 (serine 114 in hu-
man PPARγ2), which results in a constitutively more ac-
tive receptor (through inhibition of phosphorylation), are
protected from obesity-associated insulin resistance [57]; (4)
mice lacking PPARγ in fat, muscle, or liver are predisposed
to developing insulin resistance [58–61].
Importantly, studies of human PPARγ genetic variants
have provided independent validation of the pharmacolog-
ical and animal data. For example, severe insulin resistance
(with or without overt T2DM) has proved to be a remarkably
consistent finding in subjects with loss-of-function PPARγ
mutations, being evident even in early childhood in aﬀected
individuals (Figure 2) [16–23]. Equally impressive has been
the finding that of more than 40 diﬀerent reported associ-
ations of genetic variation and population risk to T2DM,
Pro12Ala has emerged as the most widely reproduced [62].
The Ala allele is protective against the risk of developing
T2DM, and it has been estimated that the global preva-
lence of T2DM would be ∼25% lower simply by virtue of
everybody carrying one or more copies of the Ala allele
[49, 62, 63], implying that PPARγ is perhaps the single most
important “diabetogene” identified to date.
In light of the findings with Pro12Ala, several groups
have sought to determine whether other single-nucleotide
polymorphisms (SNPs) within PPARγ might also influence
T2DM risk at a population level. In a study of ∼4000 Asian
subjects, a link with a second polymorphism C1431T (for
which the presence of a T allele conferred a reduced diabetes
risk when compared with CC homozygotes (OR = 0.73,
P = .011)) has been reported [64]. Other workers have taken
analysis of this genetic variant further, establishing it to be
in tight allelic disequilibrium with the Ala12 variant in a
separate study population (70% of all Ala carriers also car-
ried the C1431T polymorphism) [65]. Having genotyped in-
dividuals from three separate cohorts (1997 subjects with
T2DM, 2444 nondiabetic children, and 1061 middle-aged
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controls—all from a similar area in Tayside, Scotland) for
the PPARG Pro12Ala and C1431T polymorphisms, they con-
cluded that the Ala12 variant was underrepresented in the
T2DM population when compared with similarly aged non-
diabetic adults (OR = 0.74, P = .0006). The 1431T variant
was also underrepresented in the T2DM versus adult popula-
tion. Intriguingly however, when the Ala12 variant was on a
haplotype not bearing the 1431T variant, it conferred greater
protection (OR = 0.66, P = .003); in contrast, when it was
present in haplotypes containing the 1431T variant (70%
of Ala12 carriers), this protection was absent (OR = 0.99,
P = .94). Further studies are awaited with interest.
Thus, it is clear that the relationship between PPARγ ac-
tivity and insulin sensitivity in humans is complex, with ev-
idence for a gene dosage eﬀect, which is subject to modifica-
tion by other genetic and environmental factors.
3.2.2. Mechanisms of action
Adipose tissue
Given its high level of expression in adipose tissue and its
pivotal role in adipogenesis, it is likely that receptor activa-
tion in adipocytes contributes significantly to the clinical ef-
ficacy of PPARγ ligands in ameliorating insulin resistance.
Consistent with this, mice lacking adipose tissue have been
shown to be refractory to the antidiabetic eﬀects of TZDs
[66], while adipose-specific deletion of PPARγ (which is as-
sociated with progressive lipodystrophy) predisposes mice to
hepatic steatosis, and high-fat feeding-induced skeletal mus-
cle insulin resistance [58]. In addition, because PPARγ2 is
virtually exclusively expressed in fat cells, any metabolic ef-
fects of the Pro12Ala polymorphism, including those on glu-
cose homeostasis, are likely to be secondary to alterations in
adipose tissue metabolism. Several mechanisms have been
advanced to explain how modulating PPARγ activity in fat
benefits whole-body insulin sensitivity.
(i) Regulation of free fatty acid flux in adipocytes
Circulating levels of free fatty acids (FFAs) are a major deter-
minant of insulin sensitivity [38]. Several studies have shown
that the antidiabetic eﬃcacy of TZDs correlates with their
ability to lower circulating FFA levels [38]. Murine and cel-
lular studies indicate that PPARγ activation in adipose tis-
sue may exert coordinated eﬀects on FFA flux (promoting
uptake/trapping, while simultaneously impairing release),
through the regulation of a panel of genes involved in FFA
metabolism: adipocyte lipoprotein lipase (LPL) expression
is upregulated in response to TZD treatment, thereby po-
tentially enhancing release of FFAs from circulating lipopro-
teins [67]; simultaneous upregulation of FFA transporters
such as CD36 and FATP (fatty acid transport protein) on
the adipocyte surface facilitates their uptake [68]; TZDs
may also reduce FFA eﬄux from adipocytes through en-
hanced expression of genes that promote their storage in the
form of triglycerides (e.g., glycerol kinase directs the synthe-
sis of glycerol-3-phosphate directly from glycerol; phospho-
enolpyruvate carboxykinase permits the utilization of pyru-
vate to form the glycerol backbone for triglyceride synthesis)
[69, 70]. If similar eﬀects on FFA uptake and trapping are
observed in human adipocytes, then treatment with TZDs
and other PPARγ activators is likely to promote the safe stor-
age of FFAs in adipose tissue, and prevent “ectopic” depo-
sition in other sites such as liver and skeletal muscle, where
they are capable of inducing “lipotoxicity.” Observations in
human subjects with genetic variations in PPARγ are consis-
tent with this hypothesis. For example, it appears that even
the existing residual adipose tissue depots in individuals with
loss-of-function mutations in PPARγ are dysfunctional, re-
sulting in exposure of skeletal muscle and liver to unregu-
lated fatty acid fluxes, with consequent impairment of in-
sulin action at these sites [19]. In addition, there is evidence
that the Pro12Ala polymorphism facilitates insulin-mediated
suppression of lipolysis, hence decreasing FFA release [49]. It
is worth noting however that others have failed to detect any
relationship between circulating FFA levels and Pro12Ala sta-
tus [71].
(ii) Modulation of adipokine release
In addition to regulating circulating FFA levels, adipocytes
also serve as a rich source of signalling molecules (e.g., lep-
tin, adiponectin, tumour necrosis factor-α (TNFα), and re-
sistin), many of which have far-reaching metabolic eﬀects in
other tissues. Collectively these adipocyte-derived hormones
are referred to as adipokines, and several have been identified
as targets for transcriptional regulation by PPARγ. In gen-
eral, TZDs and other PPARγ agonists enhance the expression
of adipokines that facilitate insulin action while simultane-
ously suppressing those which are antagonistic, thereby alter-
ing the profile of adipocyte gene expression in a manner that
promotes insulin sensitization. For example, activation of
PPARγ inhibits the expression of TNFα, resistin, and retinol-
binding protein 4 (RBP4), all of which are associated with
insulin resistance [72–74]. In contrast, adiponectin gene ex-
pression is increased following TZD treatment, thereby pro-
moting fatty acid oxidation and insulin sensitivity in mus-
cle and liver [75]. Circulating adiponectin levels have been
shown to correlate closely with insulin sensitivity, and in-
versely with fat mass (especially visceral adiposity) [76], sug-
gesting that this adipokine may represent a critical link be-
tween PPARγ activation and insulin sensitization [75, 76].
Consonant with this, circulating adiponectin levels have been
shown to be dramatically reduced in individuals harbor-
ing loss-of-function PPARγ mutations when compared with
healthy controls [77, 78]. In contrast, to date, no defini-
tive correlation between the Pro12Ala polymorphism and
adipokine release has been established, with existing studies
providing conflicting results.
(iii) Promotion of glucose uptake into adipocytes
There is evidence to suggest that PPARγ is also capable of di-
rectly modulating the insulin signal transduction pathway in
adipose tissue. The GLUT4 (insulin-dependent) transporter
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is a key modulator of glucose disposal in both muscle and
fat. Binding of insulin to its tyrosine kinase receptor engages
a cascade of intracellular phosphorylation events, includ-
ing activation of phosphatidylinositol-3-OH kinase (PI(3)K)
and other downstream kinases, which promote traﬃcking of
GLUT4 containing vesicles to the plasma membrane. A sec-
ond pathway, which involves a distinct group of signalling
molecules including the c-Cbl protooncogene product and
CAP (c-Cbl-associated protein), acts in concert to augment
this process. Several groups have shown that PPARγ activa-
tion in adipose tissue can influence insulin signalling at var-
ious points in these pathways, for example, through upregu-
lation of insulin receptor substrates-1 and -2 (IRS-1, IRS-2)
[79, 80], the p85 subunit of PI(3)K [81], and CAP [82, 83]—
all of which might be predicted to enhance GLUT4 activ-
ity. Increased glucose uptake into adipocytes contributes to
whole-body glucose disposal, and provides important sub-
strate for triglyceride synthesis.
(iv) Regulation of adipocyte 11β-hydroxysteroid
dehydrogenase type 1 activity
Prolonged exposure to hypercortisolaemia, as occurs in sub-
jects with Cushing’s syndrome, is associated with many fea-
tures of the metabolic syndrome (visceral obesity, glucose
intolerance, hypertension, and dyslipidaemia). While circu-
lating cortisol levels in ordinary obese non-Cushingoid in-
dividuals are normal (if not slightly reduced), there is ev-
idence to suggest that local regeneration of cortisol within
adipose tissue could contribute to the development of in-
sulin resistance in the setting of visceral obesity [84]. 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) directs
the production of active cortisol from inactive cortisone in
liver and fat, thereby facilitating cortisol-induced adipocyte
diﬀerentiation. In keeping with this, adipose-specific overex-
pression of 11β-HSD1 in transgenic mice induced a pheno-
type of insulin resistance and central obesity [85]. PPARγ lig-
ands have been shown to downregulate adipocyte 11β-HSD1
expression and activity [86], and the subsequent modulation
of glucocorticoid-induced gene expression may conceivably
contribute to their insulin sensitizing actions. Studies of 11β-
HSD1 activity in adipose tissue from subjects with loss-of-
function mutations in PPARγ should provide a unique op-
portunity to examine the role of PPARγ in regulating human
11β-HSD1 function.
Skeletal muscle and liver
Maintenance of normal glucose homeostasis is critically de-
pendent on retention of insulin sensitivity in key target tis-
sues including liver and skeletal muscle. In addition to the
beneficial eﬀects of lowering circulating FFA levels and in-
ducing a more favorable adipokine milieu to promote insulin
sensitivity, there is some evidence to suggest that PPARγ ac-
tivation at both of these sites might directly influence glu-
cose and lipid homeostasis. For example, TZDs have been
reported to facilitate insulin-stimulated glucose uptake in
cultured human skeletal muscle cells, by enhancing insulin-
stimulated PI(3)K activity andGLUT4 translocation [87, 88].
Thus, while skeletal muscle expresses relatively low levels of
PPARγ protein when compared with adipose tissue, its dom-
inant role in insulin-mediated glucose disposal suggests that
PPARγ activation at this site may contribute significantly to
the glucose lowering eﬀect of TZD treatment. Unfortunately,
to date attempts to resolve this issue using animal models
of muscle-specific PPARγ deletion have proved unsuccess-
ful with two separate groups reporting conflicting findings
[59, 60]. Similarly, it remains to be seen whether activation
of PPARγ in human liver benefits or impairs metabolic func-
tion, with further studies needed to clarify its role in the reg-
ulation of hepatic gluconeogenesis and susceptibility to hep-
atic steatosis.
3.3. PPARγ and lipid homeostasis
As might be predicted for a group of drugs that improve in-
sulin sensitivity, TZDs raise HDL cholesterol in the majority
of treated diabetics (typically by 5%–10% ) [8]. Intriguingly
however, their eﬀects on hypertriglyceridaemia have been
somewhat more variable, with reductions in triglyceride lev-
els observed more often with pioglitazone than rosiglitazone.
One hypothesis that has been advanced to explain this appar-
ent discrepancy is that pioglitazone may also be acting as a
partial PPARα agonist (akin to a fibrate), while at the doses
used in clinical practice rosiglitazone retains pure γ-agonist
activity [89]. However, data on mechanisms underlying the
eﬀects of TZDs on lipids in humans is limited and, moreover,
caution needs to be exercised when attempting to extrapolate
from animal studies, given the significant species-specific dif-
ferences that exist in lipoprotein metabolism.
To date, virtually all subjects with loss-of-function muta-
tions in PPARγ have exhibited hypertriglyceridaemia and/or
low HDL levels, with relatively unremarkable LDL choles-
terols [16–23] (Figure 2). It remains unclear however, as to
whether these abnormalities are simply a “metabolic conse-
quence” of severe insulin resistance per se, or whether they
indicate an additive and independent eﬀect of dysfunctional
PPARγ signalling in relation to lipoprotein metabolism. Fur-
ther studies of the reverse cholesterol transport pathway
in monocyte-derived macrophages from these subjects may
help to address this important issue.
Although there is an extensive body of data concerning
the potential eﬀects of the Pro12Ala polymorphism on gly-
caemic control, there are relatively few studies focusing on
its consequences for lipid homeostasis. Moreover, given the
potential confounding eﬀect of insulin resistance, cohort se-
lection (particularly with respect to diabetic status and/or
BMI) is critical when trying to identify a specific indepen-
dent link. Accepting these limitations, there is some evi-
dence to suggest that the Ala allele may confer benefits for
HDL metabolism. For example, in the original study of Deeb
et al., higher HDL cholesterol (and lower triglyceride) levels
were observed among elderly subjects with the Ala/Ala geno-
type compared with Pro/Ala and Pro/Pro genotypes [48]. A
similar association has been described in over 4000 Singa-
pore Asians whose genotype was analyzed as a dichotomous
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variable (i.e., presence or absence of the Ala variant), and
in whom Ala allele carriers had significantly higher HDL
cholesterol compared with Pro/Pro homozygotes [64]. How-
ever, other groups have reported conflicting findings, with
some detecting an association of lower HDL cholesterol lev-
els with the presence of the Ala allele [50].
3.4. PPARγ and blood pressure regulation
Hypertension has been reported in a significant proportion
of subjects harboring PPARγ mutations [16–23]. While this
is not unexpected, given the well-recognized associations of
insulin resistance and T2DM with hypertension, it is note-
worthy that in some cases the hypertension has been of an
unusually early onset and severity [16, 19, 23]. Indeed, on
occasion it has been the dominant clinical feature, manifest-
ing even in the absence of diabetes and its associated mi-
crovascular complications. In contrast, TZD therapy is as-
sociated with a modest reduction in blood pressure in a va-
riety of clinical settings, including nondiabetic hypertensive
subjects [89]. Taken together, these findings suggest possible
additional eﬀects on blood pressure regulation, which are in-
dependent of insulin sensitivity, and indeed several lines of
evidence suggest that PPARγ may directly regulate vascular
tone, for example, through blockade of calcium channel ac-
tivity in smooth muscle, inhibition of release of endothelin-
1, and enhancement of C-type natriuretic peptide release
[89].
While no studies of vascular tone or endothelial function
have yet been reported in human subjects with PPARγ muta-
tions, mice heterozygous for the equivalent Pro465Leu mu-
tation were found to be hypertensive in the absence of in-
sulin resistance [46]. The hypertension in PpargP465L/+ mice
was associated with increased expression of RAS components
in various adipose depots—angiotensinogen (AGT) and an-
giotensin II receptor subtype 1 (AT1R) in inguinal and go-
nadal fat, respectively [46]. Interestingly, transgenic mice ex-
pressing AGT in adipose tissue have higher BP and increased
fat mass [90]. Thus, it is conceivable that modulation of RAS
activity in adipose tissue contributes to the decrease in blood
pressure, which is seen with TZDs and other PPARγ agonists.
Data relating to diﬀerences in blood pressure and
Pro12Ala status have proved less informative, with studies
again reporting conflicting findings [91, 92], which are likely
to reflect other genetic and environmental influences that are
at work in the diﬀerent study populations.
3.5. PPARγ and atherosclerosis
Collectively, the individual components of the metabolic
syndrome conspire to dramatically increase the risk of car-
diovascular disease [93]. PPARγ activation with exogenous
ligands such as the TZDs would be predicted to confer sig-
nificant benefits in this setting, through the amelioration of
insulin resistance, dyslipidaemia, and possibly hypertension,
albeit at a potential cost of mild weight gain (as a conse-
quence of enhanced adipogenesis and fluid retention). In-
deed retrospective human studies have indirectly suggested
an atheroprotective eﬀect of TZDs [94], and more recently
a prospective trial demonstrated that pioglitazone protected
patients with T2DM, albeit modestly, from cardiovascular
events [9].
It was therefore surprising and of potential therapeu-
tic concern when Tontonoz et al. reported that PPARγ ac-
tivation in a premacrophage cell line induced expression of
CD36 (also known as FAT—fatty acid translocase), a cellu-
lar scavenger receptor for atherogenic low-density lipopro-
tein (LDL) [95]. Enhanced CD36 expression might be pre-
dicted to increase intracellular accumulation of oxidized
LDL cholesterol, which could then be catabolized to gener-
ate PPARγ ligands (e.g., 9-hydroxyoctadecadienoic acid (9-
HODE) and 13-HODE) capable of further receptor activa-
tion, thereby creating a vicious feedforward cycle of increas-
ing lipid uptake, and ultimately driving conversion of the
macrophage into an atherogenic foam cell [95, 96]. The find-
ing that PPARγ is expressed at relatively high levels in hu-
man atherosclerotic plaques further served to fuel concerns
[97].
However, almost coincident with these observations, sev-
eral groups reported that PPARγ ligands could reduce the
release of inflammatory cytokines (e.g., TNF-α and IL-6)
from macrophages, an eﬀect that might be predicted to be
antiatherogenic [98, 99]. Several anti-inflammatory mecha-
nisms have been proposed, including inhibition of NF-kB,
AP1, and STAT signalling by PPARγ [100].
Subsequent studies have further redressed the balance,
with the demonstration that PPARγ ligands exert an oppos-
ing eﬀect on SR-A, a second LDL scavenger receptor, down-
regulating its expression in mouse macrophages [101]. In ad-
dition, the nuclear receptor LXRα (liver X receptor α), which
enhances expression of ABCA1 (ATP-binding cassette trans-
porter A1), a protein which mediates cellular cholesterol ef-
flux [102], has also been shown to be a PPARγ target gene
in human and mouse macrophages [103, 104]. Taken to-
gether, these data suggest a broader spectrum of PPARγ ef-
fects within the macrophage with the overall balance favour-
ing cholesterol eﬄux and an antiatherogenic eﬀect.
At first glance, the finding that only six subjects from a
cohort of more than 20 aﬀected PPARγ mutation carriers
[18, 23] have documented atheromatous coronary disease
might seem surprisingly modest, especially when one consid-
ers the severity of insulin resistance, dyslipidaemia, and hy-
pertension found in this group, coupled with the potentially
deleterious consequences of dysfunctional PPARγ signalling
inside mutant macrophages. However, it is important to note
that four of the six aﬀected subjects are/were relatively young
females in whom atheromatous coronary disease in the gen-
eral population is a relatively uncommon occurrence. Ac-
cordingly, given that many of the remaining mutation carri-
ers are still relatively young (<50 years), with a predominance
of females, it would seem premature to exclude the possibil-
ity of accelerated vascular disease in this high-risk group.
There is also an emerging body of epidemiological ev-
idence to suggest an association between the naturally oc-
curring PPARγ polymorphisms and arterial intima media
thickness (IMT), and thus indirectly, cardiovascular risk. A
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study of 154 Japanese T2DM patients found those carrying
the Ala12 allele to have a significantly lower carotid IMT
than their Pro/Pro counterparts, despite no observed diﬀer-
ences in gender, age, fasting blood glucose, lipid profile, or
HbA1c [105]. However, diﬀerences in BMI and the degree
of insulin resistance between the two groups were not re-
ported. Yan et al. used IMT as a secondary outcome measure
to investigate the prevalence of the C161T PPARγ polymor-
phism within 4 diﬀerent Chinese cohorts; 248 subjects with
insulin resistance syndrome (IRS), 163 with essential hyper-
tension, 115 with T2DM and 121 normal controls. They
observed that the CC genotype (prevalence 75%) was sig-
nificantly associated with increased IMT compared to CT
and TT genotypes (prevalence 22% and 4%, resp.) within
248 “metabolic syndrome” patients [106]. However inter-
estingly, the prevalence of neither the Pro12Ala nor C161T
polymorphism within PPARγ was overrepresented in a large
Caucasian cohort (1170 individuals) with angiographically
proven coronary heart disease [50], and it is clear that fur-
ther large-scale studies are needed.
4. SELECTIVE PPARγ MODULATION
The ability of TZDs such as rosiglitazone and pioglitazone
to enhance insulin sensitivity makes them attractive agents
for use in the treatment of T2DM and the metabolic syn-
drome. Unfortunately however, the initial excitement that
followed the introduction of TZDs into clinical practice has
been tempered by the realization that for many patients, they
aﬀord only modest benefits in terms of glycaemic control—
typically lowering glycosylated haemoglobin levels by 1.0%–
1.5%—at a cost of weight gain and, in some instances, fluid
retention/peripheral oedema [8]. Nevertheless, they repre-
sent a “step in the right direction” and have served to em-
phasize the potential benefits and limitations of modulating
PPARγ function in human subjects.
For those seeking to develop the next generation of
PPARγ ligands, two (related) key questions must be an-
swered: (1) how much PPARγ activation is desirable, (2)
is it possible to separate the receptor’s adipogenic actions
from those mediating improved insulin sensitivity, that is, to
develop selective receptor modulators (so-called SPPARMs)
that are capable of regulating glucose and lipid metabolism
without promoting adipogenesis. Taking this a step fur-
ther, if such agents favourably altered receptor function at
other sites, for example, within macrophages and the vas-
culature, then it is conceivable that we might have access
to a class of drugs which is almost tailor-made for treating
the metabolic syndrome. Precedent for such an approach is
provided by raloxifene, a selective oestrogen receptor (ER)
modulator (SERM), which is an ER antagonist in breast and
endometrium, but an agonist in bone. Examination of the
properties of PPARγ in adipocytes suggests that it may be
possible to selectively modulate its function in an analo-
gous manner. For example, inside mature adipocytes, certain
PPARγ target genes, for example, GyK, require exogenous
ligand for activation, while others, for example, aP2, are ac-
tivated even in the absence of synthetic ligand [24]. The con-
cept of diﬀerential modulation of PPARγ activity is also sup-
ported by the work of Li and Lazar who have demonstrated
that a form of this protein rendered constitutively active by
fusion to the powerful VP16 transactivation domain could
switch on the adipogenic gene program, yet it was unable to
transrepress other PPAR target genes such as that encoding
resistin [107].
Promisingly, several groups have independently identi-
fied PPARγ ligands with partial agonist activity and only
mild/modest eﬀects on adipogenesis, yet with retention of
insulin sensitizing properties. MCC-555 is one such com-
pound, whose ability to stimulate PPARγ is highly context-
specific [108]. FMOC-L-Leucine, a chemically distinct re-
ceptor ligand, whose gene-specific eﬀects appear to reflect
diﬀerential coactivator recruitment, has been shown to im-
prove insulin sensitivity, yet exert relatively weak adipogenic
eﬀects in rodent diabetic models [109]. Similarly, YM440, an
analog of the oxadiazolidinediones, improved glycaemic con-
trol, but did not alter body fat weight in diabetic db/db mice
[110].
The discovery of such compounds has prompted wide-
spread screening of libraries of both structurally related and
chemically distinct molecules with the subsequent identifi-
cation of an array of potential SPPARMs: PAT5a, an unsat-
urated TZD with partial agonist activity, is a potent antidi-
abetic agent with only weak adipogenic activity [111]; sim-
ilar properties have been reported for the novel non-TZD-
selective PPARγ modulators nTZDpa [112] and KR-62980
[113]; a panel of N-benzyl-indole-selective PPARγ modula-
tors, with partial agonist activity in vitro, exhibited potent
glucose-lowering activity in db/db mice, but attenuated in-
creases in heart weight and brown adipose tissue when com-
pared with full agonists [114]. Interestingly, the message that
seems to be emerging from these and other similar stud-
ies is that ‘activation in moderation’ is the way forward for
PPARγ, thus confirming the adage that you can indeed have
‘too much of a good thing.’
5. CONCLUSIONS
In just over a decade, PPARγ has evolved from modest be-
ginnings as a simple regulator of adipogenesis to become a
key therapeutic target in the fight against the 21st century
epidemics of obesity, insulin resistance, and the metabolic
syndrome. While pharmacological and animal studies have
yielded important information regarding the role of this re-
ceptor in the regulation of energy, glucose, and lipid home-
ostasis, there is little doubt that defining the metabolic
consequences associated with polymorphisms and muta-
tions in the human PPARγ gene has contributed signifi-
cantly to our understanding of the biology of this recep-
tor. Given the significant species-specific diﬀerences that ex-
ist in metabolism, particularly in relation to lipid home-
ostasis, it is critical that we continue to identify and study
these human experiments of nature, in order to comple-
ment the impressive pharmacological and functional ge-
nomic approaches that are currently being used to facilitate
the development of more superior ligands with enhanced
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therapeutic impact. Given the apparent inexorable rise in
the prevalence of obesity, insulin resistance, and T2DM,
the need for such novel therapies could not be more ur-
gent.
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